Company / Cash & Equivalents
Nuvalent, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$261.7M
FY2025
5-year range
$68.5M / $335.4M
FY2021-FY2025
Trend
+79.7%
vs FY2024
Sector context
#68 of 207
Health Care
What the data says
At $262M, Nuvalent, Inc.'s cash & equivalents ranks #68 of 207 in the Health Care sector. Declined from $335M to $262M over the past 2 years.
Based on SEC 10-K filings.
$262M in FY2025 with a 5-year CAGR of +90.9%.
Declined from $335M to $262M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +2.7%
- 5-Year CAGR
- +90.9%
- 10-Year CAGR
- -
Sector benchmark
#68 of 207 in Health CareTop 33% of 207This company $261.7M Sector average $669.5M
▼
-60.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +90.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 79.7% year-over-year.
- Ranks #68 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $261.7M | +79.7% |
| FY2024 | $145.7M | -56.6% |
| FY2023 | $335.4M | +38.7% |
| FY2022 | $241.8M | +252.9% |
| FY2021 | $68.5M | +563.2% |
| FY2020 | $10.3M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026